ATLAS Market profile
Menu
Atlas ¡ Symbols ¡ ETFs ¡ CRCA

Atlas market file ¡ Etf ¡ United States

ProShares Ultra CRCLCRCA

Last close
13.33
Change
+11.08%
96-bar range
10.07 – 80.32
As of
7 Aug 2026

ProShares Ultra CRCL is an exchange-traded fund listed as CRCA on AMEX. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.

Identity
Nasdaq Trader
Chart rail
TradingView
File state
Public profile
Atlas chart snapshot AMEX:CRCA

Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.

82.427563.811245.19526.57877.962523 Mar01 Jun07 Aug

▮ up candle   ▮ down candle

Latest close13.33
Day change+11.08%
Window high80.32
Window low10.07
96-bar change-83.24%
SnapshotDaily ¡ 96 bars
As of2026-08-07 13:30 UTC

Weekly outlook: the last 54 weekly closes (-94.43% over the window).

248.512.415204 Aug07 Aug

Source rail: Yahoo Finance chart API (CRCA). This dated snapshot is the crawlable Atlas reference.

Live market viewTradingView ¡ provider feed Open view

Open the attributed TradingView market view for CRCA. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.

Loading the attributed market view...

Open full TradingView chart ->

At a glance

CRCA public profile

Company

Exchange-traded fund. ProShares Ultra CRCL is connected to current market context, cited company sources and its retained research file.

Market

ProShares Ultra CRCL trades as CRCA on AMEX. ProShares Ultra CRCL (CRCA) has a latest verified close of 13.33, up 11.08%, dated 7 Aug 2026.

Research

Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. CRCA stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.

Institutional Market Wit ● Sourced Research File

The ProShares Ultra CRCL (CRCA) isn't a shiny new theme park with rides named after market moonshots; it's a 2 concentrated bet on a single thematic ETF that quietly shuffles between a portfolio of US-listed stocks focused on carbon credits and clean energy. The fund's mandate reads like a climate brochure-until you notice the top line: a 0.95% annual fee that lands on your statement before you've even decided whether carbon credits are the new gold. The issuer's own product rail cheerfully admits ProShares specialises in geared ETFs, but the fine print on CRCA's page is less about saving the planet and more about saving the wrapper's revenue (source: ProShares Official ETF issuer, https://www.proshares.com/).

Unlock 25 custom research runs/day, 104-week candle charts, PDF report downloads & 500-symbol watchlist.

Unlock Atlas Pro — £12/mo Open Free Workstation Run →
Daily answer

What changed for ProShares Ultra CRCL today

Open full report
CRCA daily contextvalidated public digest8 source rail2026-08-07 02:40 UTC

ProShares Ultra CRCL (CRCA) is a 2× concentrated ETF that tracks the daily performance of the Solactive Carbon Credits Index, a narrow basket of clean-energy and carbon-credit-linked US equities. The fund’s mandate is marketed as a climate-conscious growth play, but the wrapper’s revenue engine is the 0.95% annual management fee-charged whether the carbon credits rally or collapse. The issuer’s own product rail places CRCA in the same concentrated basket as 2× semiconductor and cloud-computing ETFs, a positioning that feels more about fee extraction than thematic purity (source: ProShares Official ETF issuer, https://www.proshares.com/).

The fund’s positioning under ProShares’ ‘strategic and tactical opportunities to enhance returns and manage risk’ banner places CRCA alongside concentrated bets on sectors with far deeper liquidity and clearer benchmarks. CRCA’s daily objective is tied to an index that rebalances without a public schedule, leaving investors to guess how often the basket’s concentration risk is reset. The issuer’s risk disclosures warn of ‘imperfect benchmark correlation’ and ‘leverage and market price variance,’ which is fund-speak for ‘this fund can move twice as fast in either direction’ (source: Browse ProShares ETFs by Performance & Asset Class, https://www.proshares.com/our-etfs/find-proshares-etfs?strategy=Ex-Sector&product=Product+Overview+&search=).

CRCA is listed on Nasdaq, where its trading page shows liquidity metrics that are thin relative to broader sector ETFs, reflecting the niche nature of its underlying index. The issuer’s ‘Explore concentrated and inverse ETFs’ rail lists CRCA under sector concentrated funds, but the evidence offers no AUM, daily volume, or tracking error disclosures beyond the issuer’s marketing slide. The fund’s SEC filing route exists, but the evidence rail contains no filed figures for AUM, expense accruals, or index rebalancing cadence (source: SEC EDGAR fund search for CRCA, https://www.sec.gov/edgar/search/#/q=CRCA).

For investors tempted by the thematic pitch, the practical reality is a 2× concentrated bet on a narrow, rebalancing-agnostic index, wrapped in a fee that lands before the carbon credits have a chance to prove themselves. The issuer’s own product rail positions CRCA as a sector concentrated ETF, not a climate solution, which should sharpen the focus on the mechanics rather than the marketing (source: Nasdaq CRCA market activity page, https://www.nasdaq.com/market-activity/etf/crca).

The fund’s presence on Nasdaq’s market activity page confirms ticker availability but offers no depth on spreads, depth, or intraday volume-leaving traders to infer liquidity from thin evidence. The issuer’s broader warnings about non-diversification, derivatives use, and benchmark correlation sit unchallenged by any filed AUM or tracking-error data in the evidence rail, making the wrapper’s revenue story easier to verify than its investment thesis (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/).

Sources & evidence ¡ 8 links

This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.

Ticker
CRCA
Exchange
AMEX
Sector
Us Public Etf Directory
Region
United States
Asset class
Etf
Directory source
Nasdaq Trader
TradingView

CRCA technical readout

Trend strength (ADX 14)
20.1
Average true range (ATR 14)
2.6758
ATR as % of price
21.34%
Volatility compression (ATR14/ATR50)
0.48x

Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.

Source authority

CRCA evidence rails

Atlas uses the specific public rails available for CRCA: Nasdaq Trader, TradingView, FRED, Atlas methodology. Source names identify the public evidence trail; no partnership, sponsorship or endorsement is implied.

Sources & evidence ¡ 4 rails

Open an Atlas research path on CRCA

FreedomCore Atlas can expand this public profile into source-led research files with holdings and concentration, index methodology, exposure and overlap, fees and tracking difference, and liquidity context. Each path keeps the underlying public sources visible.

Open Atlas workstation ->
📄
Institutional Research PDF Available for CRCA Verified 104-week candle chart, SEC filing evidence & risk register.
Download PDF
Atlas Pro

Keep CRCA research in your Atlas archive

Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. ÂŁ12/month founding price, locked for life. Research only; not investment advice.

Checking Atlas access...

CRCA FAQ

What is ProShares Ultra CRCL (CRCA)?ProShares Ultra CRCL (CRCA) has a latest verified close of 13.33, up 11.08%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed...

ProShares Ultra CRCL (CRCA) has a latest verified close of 13.33, up 11.08%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.

What does Atlas show for CRCA?ProShares Ultra CRCL (CRCA) has a latest verified close of 13.33, up 11.08%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources,...

ProShares Ultra CRCL (CRCA) has a latest verified close of 13.33, up 11.08%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. CRCA stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.

How often is the CRCA page updated?The CRCA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...

The CRCA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.

Which sources does Atlas use for CRCA?The CRCA file starts with Nasdaq Trader and TradingView AMEX:CRCA. The page separates verified market context from company evidence and shows open evidence gaps instead...

The CRCA file starts with Nasdaq Trader and TradingView AMEX:CRCA. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.

Can Atlas run a full research brief on CRCA?Yes. The workstation can open CRCA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.

Yes. The workstation can open CRCA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.

Is this CRCA page investment advice?No. The CRCA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...

No. The CRCA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.

Methodology

This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.

Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.

Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →